Evidence map›Paper›PMID 42967827›Full record

ArticleJAMA cardiology2026

Microvascular Resistance Reserve and Outcomes in Angina and Nonobstructive Coronary Artery Disease.

Behruz Yosofi, Aimane Mechroubi, Annemiek de Vos, Valeria Paradies, Caïa Crooijmans, Fleur W Adriaansen, Tijn P J Jansen, Aysun Cetinyurek-Yavuz, Suzette Elias-Smale, Aukelien C Dimitriu-Leen and 4 more

Abstract read
In one paragraph

Article in JAMA cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Behruz YosofiDepartment of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Aimane MechroubiDepartment of Cardiology, UMC Utrecht, Utrecht, the Netherlands.
Annemiek de VosDepartment of Cardiology, Catharina Hospital, Eindhoven, the Netherlands.
Valeria ParadiesDepartment of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands.
Caïa CrooijmansDepartment of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Fleur W AdriaansenDepartment of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Tijn P J JansenDepartment of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Aysun Cetinyurek-YavuzDepartment of IQ Health Science, Radboudumc, Nijmegen, the Netherlands.
Suzette Elias-SmaleDepartment of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Aukelien C Dimitriu-LeenDepartment of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Tim P van de HoefDepartment of Cardiology, UMC Utrecht, Utrecht, the Netherlands.
Niels van RoyenDepartment of Cardiology, Radboudumc, Nijmegen, the Netherlands.
Peter DammanDepartment of Cardiology, Radboudumc, Nijmegen, the Netherlands.
NL-CFT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Coronary microvascular dysfunction (CMD) is highly prevalent in patients with angina and nonobstructive coronary arteries (ANOCA). Microvascular resistance reserve (MRR) is a novel index to assess CMD independently of epicardial disease and driving pressures, but the long-term prognostic value of continuous thermodilution-derived MRR in patients with ANOCA is unknown. Objective: To assess the prognostic value of continuous thermodilution-derived MRR and its association with clinical outcomes and symptom burden in patients with ANOCA. Design, Setting, and Participants: This prospective, multicenter cohort study within the Netherlands Registry of Invasive Coronary Vasomotor Function Testing (NL-CFT) included patients between July 2020 and June 2025 in 4 clinical centers in the Netherlands. Follow-up for clinical events and patient-reported symptoms was completed for up to 3 years. Clinical events were adjudicated by investigators blinded to CFT results. Consecutive patients with ANOCA who underwent continuous thermodilution were included. Exposure: Abnormal MRR (CMD) was defined as less than 2.1, gray zone as 2.1 to 2.7, and normal microvascular function as 2.7 or greater. Main Outcomes and Measures: The primary clinical outcome was a composite of all-cause death, acute coronary syndrome, stroke, clinically indicated revascularization, repeat angiography without intervention, and unplanned hospital admittance or emergency department visit due to angina or heart failure. Secondary outcomes included angina at baseline and follow-up. Symptoms were assessed using the patient-reported Seattle Angina Questionnaire (SAQ) scores. Results: Among 553 included patients (mean [SD] age, 59.1 [9.6] years; 459 female [83.0%]) with a mean (SD) follow-up of 27.5 (16.1) months, CMD was observed in 94 patients (17.0%). The main composite outcome did not differ across the 3 MRR categories (18 of 94 patients with abnormal [19.1%] vs 21 of 98 patients with gray zone [21.4%] vs 76 of 361 patients with normal [21.1%] MRR; log-rank P = .85). Individual outcomes did not differ between groups. There was no overall longitudinal interaction between MRR and SAQ summary scores. While low MRR (abnormal vs normal groups) was not associated with an increased symptom burden at baseline, it was associated with worse angina at follow-up (mean [SD] SAQ summary score, 53.0 [16.7] vs 60.1 [16.6]; P = .04) and less clinically relevant improvement (9 of 30 patients [30.0%] vs 52 of 88 patients [59.1%]; P = .02). Conclusions and Relevance: In this study, CMD assessed by continuous thermodilution-derived MRR was not associated with clinical outcomes.

Identifiers

PMID42967827
PMCPMC13725768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.